IPHAInnate Pharma SAvs its industry peers
A metric-by-metric comparison of Innate Pharma SA against SIC 2836 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Empresa | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IPHAEsta | $180M#6 | — | — | — | — | — | — | — | — | — | -4.0%#2 | — |
| EVAX | $1.4B#3 | — | — | 181.7x#3 | 125.1%#3 | 27.1%#3 | -122.7%#3 | — | — | — | — | — |
| FENC | $372M#5 | — | 8.8x#2 | 8.3x#2 | -6.1%#5 | -2134.2%#7 | -14.1%#2 | -22951.3%#2 | -23.1%#2 | — | — | — |
| GNTA | $17M#9 | — | — | — | — | — | — | — | — | — | — | — |
| GPLB | — | — | — | — | — | -0.8%#4 | — | — | — | — | — | — |
| IMCR | $1.6B#2 | — | 3.9x#1 | 4.1x#1 | 29.0%#4 | 30.5%#2 | -11.3%#1 | -8.5%#1 | -12.1%#1 | — | -4.6%#3 | — |
| IMTX | $1.2B#4 | — | — | — | — | — | — | — | — | — | 30.4%#1 | — |
| MEOBF | — | — | — | — | 191.4%#1 | -16.1%#5 | — | — | — | — | — | — |
| MESO | $19.6B#1 | — | — | 1141.7x#4 | 191.4%#1 | -16.1%#5 | — | — | — | — | — | — |
| MOLN | $155M#7 | — | — | — | — | — | — | — | — | — | — | — |
| OKYO | $71M#8 | — | — | — | — | 72.0%#1 | — | — | — | — | — | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2836). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. Esta tabla agotó el tiempo durante su construcción, por lo que cubre parte del grupo; los rangos son solo dentro de las filas mostradas y se completará en breve. Table built 2026-09-19.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice